Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Tuesday, May 27, 2025, inter-alia considered and approved the following:1. Audited Financial Results2. Dividend3. Appointment of Secretarial AuditorsThe Meeting of the Board of Directors of the Company commenced at 03:30 p.m. and concluded at 04.10 p.m.Kindly take the above information on your records.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Supriya Lifescience held a meeting on May 27, 2025, from 3:30 p.m. to 4:10 p.m. During the meeting, the Board approved the Audited Financial Results for the period under review. The Board also approved a dividend for shareholders. Additionally, Secretarial Auditors were appointed. Detailed financial figures, dividend amount, and auditor identity are not disclosed in this filing.
The approval of audited results and dividend is generally positive for shareholders, suggesting the company has completed its annual audit and is in a position to reward shareholders. Investors should wait for the detailed audited results and the dividend amount to assess the actual impact.